All News
Meng et al. ESR/CRP and steroid associated increased risk of MACE in IA. NSAIDs/COX-2 and MTX associated reduced risk of MACE in IA. @RheumNow #ACR22 Abstr#1207 https://t.co/OvjNZkpWpy https://t.co/9NMIJPcV9G
Richard Conway RichardPAConway ( View Tweet)
Singh @NamrataRheum et al. 27,421 RA patients, 8225 on b/tsDMARD. b/tsDMARDs did not increase risk of lymphoma. IR 1.68/1000PY (95% CI 1.5-1.9) on csDMARD vs IR 1.73/1000PY (95%CI 1.4-2.1) on b/tsDMARD. @RheumNow #ACR22 Abstr#1210 https://t.co/3Uvz3mvsGM https://t.co/6k3Vqb21KF
Richard Conway RichardPAConway ( View Tweet)
FIND-RA study from Belgium attempts to quantify ILD in early RA. Previously wide ranging estimates 5-20%. They found ILD in 13%. Awaiting full data on ILD severity and progression.
@RheumNow ABST1393 #ACR22
https://t.co/ol4iCTkbn9 https://t.co/RLG1ur21dj
Julian Segan JulianSegan ( View Tweet)
Juge @Juge_P_A @PhilippeDieude et al. RA-ILD patients have shorter telomere length than RA without ILD. RA-ILD similar telomere length to IPF. OR 0.54 for RA-ILD. Assoc with FVC%pred also. @RheumNow #ACR22 Abstr#1122 https://t.co/H5A7unpjjB https://t.co/IjvHmupykM
Richard Conway RichardPAConway ( View Tweet)
QD205 - RA Activity During Pregnancy (abstract #0955) #ACR22
28 yoF with active RA during Pregnancy - What are your treatment options?
https://t.co/jj99qjugFG https://t.co/vioX8xZw0D
Links:
Dr. John Cush RheumNow ( View Tweet)
DANBIO registry: 1600+ pts RA, AxSpA, PsA
Infiximab biosimilar to biosimilar switch (CT-P13 -> GP1111)
Maintenance at 1yr:
>80%
> withdrawal in original IFX naive, but higher BL DA
Do second time switchers do better because of past switch experience?
Abs#1112 #ACR22 @RheumNow https://t.co/IgjhGLVESz
Aurelie Najm AurelieRheumo ( View Tweet)
Yes. But this only accounts for 1/3 of risk to develop clinical RA.
We need a better understanding of the other 2/3 so we can propose efficient preventive interventions.
#ACR22 @RheumNow https://t.co/RRzlAISFK3
Aurelie Najm AurelieRheumo ( View Tweet)
Biosimilar to biosimilar effective in treatment of RA/PsA/AxSpA.
Large study looking at infliximab biosimilar switching - resulted in high retention rates and virtually no change in disease activity.
@RheumNow #ACR22 Abs#1112 https://t.co/uNRXLewo4M
Robert B Chao, MD doctorRBC ( View Tweet)
Most important point from the Great Debate on treating pre-RA.
Are we really treating to prevent RA or are we simply delaying RA onset?
I don't think there is enough data to treat pre-clinical RA with our current arsenal of DMARDs.
What would you do?
@RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
ACPA+ ~40% did not convert to clinical RA
RF+/ACPA+ least likely to seroconvert to negative
@RheumNow #ACR22 https://t.co/djVPKDdWjz
Robert B Chao, MD doctorRBC ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
US erosions in 5th MTPs predict clinical arthritis in +CCP "Pre-RA" patients
~15% of patients will develop RA
@RheumNow #ACR22 https://t.co/jS2YMlF4iO
Robert B Chao, MD doctorRBC ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
"The more good factors you have, the less likely you will develop RA"
- Janet Pope
Never smoker, normal BMI, low EtOH, exercise, healthy diet
@RheumNow #ACR22 https://t.co/jIMOn8ht6u
Robert B Chao, MD doctorRBC ( View Tweet)
#ACR22 The Great Debate: to treat subclinical #Rheumatoidarthritis or not. @Janetbirdope counted hands manually in person. Let's check out the #socialmedia community. What is your definition of sub-clinical RA? @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Infections in pre-RA: a cause or a consequence?
Rheumatoid arthritis is known to be associated with a higher risk of infections, and this occurs for multiple reasons: immune dysfunction, systemic inflammation, comorbidities, and treatments.
https://t.co/N91Goop92l https://t.co/yvnRrsHSCB
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Michael Holers on preclinical RA
"Individuals who are anti-CCP positive are not clinically well. We just can't see what is going on"
@RheumNow #ACR22
Robert B Chao, MD doctorRBC ( View Tweet)
The Great Debate! Should you treat pre-clinical RA?
First - likelihood of RA?
If you have +ACPA or RF in sputum, there is 67% chance of developing clinical RA!
@RheumNow #ACR22 https://t.co/K7pUhvbEDR
Robert B Chao, MD doctorRBC ( View Tweet)
The great debate
Next steps to develop RA prevention
Kevin Deane
“It’s time to move from disease modifying drugs to disease modifying therapeutic approaches”
#ACRdebate #ACR22 @RheumNow https://t.co/3vt58sXlDx
Aurelie Najm AurelieRheumo ( View Tweet)
Multiplex peripheral blood in 200+ ILD pts
Differences in IL-17 RD-ILD>IPF> IPAF
Higher IL-13 strongly asso w/ non-progression of ILD in RD-ILD, IPF & IPAF
OR 0.4
Almost surprising considering known profibrotic role of IL-13 🧐
https://t.co/21UMq6w9hI
Abs#1109 #ACR22 @Rheumnow https://t.co/7tfk74zH8A
Aurelie Najm AurelieRheumo ( View Tweet)
There are good reasons why you might want to treat pre-RA. Hard to walk past this promise #ACR22 @RheumNow https://t.co/YHmIl5dsID
David Liew drdavidliew ( View Tweet)
USA vs Canada
It's kicking off
and a super hot topic
The Great Debate: To Treat or Not? The Role of DMARDS in Subclinical Rheumatoid Arthritis
Holers/Deane (treat 🇺🇸)
El Gabalawy/Pope (don't treat 🇨🇦)
What more do you want, #ACR22? Bring it on @RheumNow https://t.co/DroQdnSQHf
David Liew drdavidliew ( View Tweet)
